Gastrointestinal Cancer

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

Anjana Pillai, MD, detailed how the treatment landscape for HCC is evolving, highlighting data from EMERALD-1.

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

Anjana Pillai, MD, details a patient case study and key takeaways from a presentation she gave at an OncLive® State of the Science Summit™ on locoregional therapies for HCC.

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Liver transplantation plus chemotherapy demonstrated no concerning safety signals or long-term deterioration in QOL in patients with definitively unresectable CRC liver metastasis.

Switch ramucirumab/paclitaxel maintenance improved PFS and OS outcomes vs chemotherapy continuation in HER2-negative gastric or GEJ cancer.

HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.

Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Daniel M. Halperin, MD, details the FDA approval of lutetium Lu 177 dotatate as well as safety and efficacy data in pediatric and adult patients treated with the agent.

Lutetium Lu 177 dotatate with octreotide led to a clinical benefit in PFS and ORR regardless of tumor grade or primary origin in advanced grade 2 and grade 3 GEP-NETs.

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

State of the Science Summit - Gastrointestinal Cancer: Chaired by Chih-Yi Liao, MD

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

Suneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Frontline toripalimab plus bevacizumab improved progression-free survival and overall survival vs sorafenib in patients with advanced hepatocellular carcinoma.

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.